Stanley C Xie, Yinuo Wang, Craig J Morton, Riley D Metcalfe, Con Dogovski, Charisse Flerida A Pasaje, Elyse Dunn, Madeline R Luth, Krittikorn Kumpornsin, Eva S Istvan, Joon Sung Park, Kate J Fairhurst, Nutpakal Ketprasit, Tomas Yeo, Okan Yildirim, Mathamsanqa N Bhebhe, Dana M Klug, Peter J Rutledge, Luiz C Godoy, Sumanta Dey, Mariana Laureano De Souza, Jair L Siqueira-Neto, Yawei Du, Tanya Puhalovich, Mona Amini, Gerry Shami, Duangkamon Loesbanluechai, Shuai Nie, Nicholas Williamson, Gouranga P Jana, Bikash C Maity, Patrick Thomson, Thomas Foley, Derek S Tan, Jacquin C Niles, Byung Woo Han, Daniel E Goldberg, Jeremy Burrows, David A Fidock, Marcus C S Lee, Elizabeth A Winzeler, Michael D W Griffin, Matthew H Todd, Leann Tilley
Malaria poses an enormous threat to human health. With ever increasing resistance to currently deployed drugs, breakthrough compounds with novel mechanisms of action are urgently needed. Here, we explore pyrimidine-based sulfonamides as a new low molecular weight inhibitor class with drug-like physical parameters and a synthetically accessible scaffold. We show that the exemplar, OSM-S-106, has potent activity against parasite cultures, low mammalian cell toxicity and low propensity for resistance development...
January 31, 2024: Nature Communications